JP2022546048A5 - - Google Patents

Info

Publication number
JP2022546048A5
JP2022546048A5 JP2022513203A JP2022513203A JP2022546048A5 JP 2022546048 A5 JP2022546048 A5 JP 2022546048A5 JP 2022513203 A JP2022513203 A JP 2022513203A JP 2022513203 A JP2022513203 A JP 2022513203A JP 2022546048 A5 JP2022546048 A5 JP 2022546048A5
Authority
JP
Japan
Prior art keywords
methyl
pyrimidine
oxo
dihydropyrido
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022513203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546048A (ja
JP7650864B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/048070 external-priority patent/WO2021041588A1/en
Publication of JP2022546048A publication Critical patent/JP2022546048A/ja
Publication of JP2022546048A5 publication Critical patent/JP2022546048A5/ja
Application granted granted Critical
Publication of JP7650864B2 publication Critical patent/JP7650864B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022513203A 2019-08-28 2020-08-27 Ｔ細胞アクティベーターとして有用な置換ピリドピリミジノニル化合物 Active JP7650864B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962892799P 2019-08-28 2019-08-28
US62/892,799 2019-08-28
PCT/US2020/048070 WO2021041588A1 (en) 2019-08-28 2020-08-27 Substituted pyridopyrimidinonyl compounds useful as t cell activators

Publications (3)

Publication Number Publication Date
JP2022546048A JP2022546048A (ja) 2022-11-02
JP2022546048A5 true JP2022546048A5 (enExample) 2023-07-20
JP7650864B2 JP7650864B2 (ja) 2025-03-25

Family

ID=72422304

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513203A Active JP7650864B2 (ja) 2019-08-28 2020-08-27 Ｔ細胞アクティベーターとして有用な置換ピリドピリミジノニル化合物

Country Status (27)

Country Link
US (3) US11584747B2 (enExample)
EP (1) EP4021901B1 (enExample)
JP (1) JP7650864B2 (enExample)
KR (1) KR102980691B1 (enExample)
CN (1) CN114302884B (enExample)
AR (1) AR119821A1 (enExample)
AU (1) AU2020336089C1 (enExample)
BR (1) BR112022001862A2 (enExample)
CA (1) CA3149594A1 (enExample)
CL (1) CL2022000485A1 (enExample)
CO (1) CO2022002424A2 (enExample)
DK (1) DK4021901T3 (enExample)
ES (1) ES3057035T3 (enExample)
FI (1) FI4021901T3 (enExample)
HR (1) HRP20251203T1 (enExample)
IL (1) IL290965B2 (enExample)
LT (1) LT4021901T (enExample)
MX (1) MX2022002271A (enExample)
PE (1) PE20220712A1 (enExample)
PL (1) PL4021901T3 (enExample)
PT (1) PT4021901T (enExample)
RS (1) RS67362B1 (enExample)
SI (1) SI4021901T1 (enExample)
SM (1) SMT202500489T1 (enExample)
TW (1) TW202122395A (enExample)
WO (1) WO2021041588A1 (enExample)
ZA (1) ZA202203515B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478621B2 (en) 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
WO2021127554A1 (en) * 2019-12-19 2021-06-24 Bristol-Myers Squibb Company Combinations of dgk inhibitors and checkpoint antagonists
CA3162979A1 (en) 2019-12-23 2021-07-01 Upender Velaparthi Substituted piperazine derivatives useful as t cell activators
IL294148A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinazolinyl compounds are useful as t-cell activators
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
CA3180670A1 (en) 2020-04-24 2021-10-28 Bayer Aktiengesellschaft Substituted aminothiazoles as dgkzeta inhibitors for immune activation
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
MX2023014762A (es) * 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
CA3228862A1 (en) * 2021-08-03 2023-02-09 Beigene, Ltd. Pyrazolopyridinone compounds
IL315015A (en) 2022-03-01 2024-10-01 Insilico Medicine Ip Ltd Diacylglycerol kinase (DGK) alpha inhibitors and their uses
WO2023165525A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2023184327A1 (en) * 2022-03-31 2023-10-05 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof
CN117088874A (zh) * 2022-05-19 2023-11-21 轩竹生物科技股份有限公司 二酰甘油激酶抑制剂及其用途
WO2023229375A1 (ko) * 2022-05-25 2023-11-30 주식회사 엘지화학 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
KR20230164602A (ko) * 2022-05-25 2023-12-04 주식회사 엘지화학 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
CN119998295A (zh) 2022-06-08 2025-05-13 因赛特公司 作为dgk抑制剂的三环三唑并化合物
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
CN117534665A (zh) * 2022-08-01 2024-02-09 山东轩竹医药科技有限公司 二酰甘油激酶抑制剂
KR20250061756A (ko) * 2022-09-08 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
CA2489560A1 (en) 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
GB0230018D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
WO2004087880A2 (en) 2003-03-26 2004-10-14 Bayer Pharmaceuticals Corporation Compounds and their use to treat diabetes and related disorders
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
CA2533626A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
JP2007503388A (ja) 2003-08-22 2007-02-22 アバニール・ファーマシューティカルズ マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用
US7381401B2 (en) * 2004-01-08 2008-06-03 The University Of Chicago T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
JP2007308402A (ja) 2006-05-17 2007-11-29 Sumitomo Chemical Co Ltd シンナモイル化合物及びその用途
JP2007308441A (ja) 2006-05-22 2007-11-29 Sumitomo Chemical Co Ltd 含複素環化合物及びその用途
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
AU2008353145B2 (en) 2008-01-03 2013-09-12 Universite D' Aix-Marseille Bitherapy and tritherapy used for treating an HIV-positive patient
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042489A2 (en) 2008-10-06 2010-04-15 Emory University Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
IN2015DN02826A (enExample) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
US9133164B2 (en) 2011-04-13 2015-09-15 Innov88 Llc MIF inhibitors and their uses
NO2694640T3 (enExample) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
US9006257B2 (en) 2012-02-09 2015-04-14 Glenmark Pharmaceuticals S.A. Bicyclic compounds as mPGES-1 inhibitors
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
AU2016245864C1 (en) 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
WO2017177037A1 (en) 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US12187687B2 (en) 2017-06-26 2025-01-07 University Of Virginia Patent Foundation Compositions and uses thereof
CN109575016B (zh) 2017-09-28 2022-01-04 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
SG11202012973RA (en) 2018-06-27 2021-01-28 Bristol Myers Squibb Co Naphthyridinone compounds useful as t cell activators

Similar Documents

Publication Publication Date Title
HRP20251203T1 (hr) Supstituirani piridopirimidinonil spojevi korisni kao aktivatori t-stanica
JP5152518B2 (ja) 置換イソキサゾリン化合物及び有害生物防除剤
KR101151325B1 (ko) 이속사졸린 치환 벤즈아미드 화합물 및 유해생물 방제제
JP2021529191A5 (enExample)
CN102149695B (zh) 异*唑啉取代的苯甲酰胺化合物的制造方法
JP5206993B2 (ja) イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
HRP20231253T1 (hr) Supstituirani spojevi naftiridina korisni kao aktivatori t stanica
JP5316808B2 (ja) 置換イソキサゾリン又はエノンオキシム化合物および有害生物防除剤
KR101416521B1 (ko) 이속사졸린치환 벤즈아미드 화합물 및 유해 생물 방제제
US8008292B2 (en) Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
US8268754B2 (en) Substituted dihydroazole compound and pest control agent
JP5820056B2 (ja) Ｃｅｔｐ阻害剤としてのシクロアルケニルアリール誘導体
JP2017533958A5 (enExample)
KR20100064382A (ko) 치환 이속사졸린 화합물 및 유해생물 방제제
JP2016516737A (ja) 新規ピリジン誘導体
JP2013500997A5 (enExample)
KR20090031898A (ko) 펜타디엔아미드 유도체
JP2017523223A5 (enExample)
WO2017192304A1 (en) Arylcarboxamides and uses thereof
RU2382784C2 (ru) Новые пиперидинзамещенные диаминотиазолы
EP2792360A1 (en) (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
JP2015155401A (ja) 置換ヘテロ環化合物及び有害生物防除剤
KR20230164600A (ko) 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도